In India, the Danish drug maker Novo Nordisk is the market leader and presently claims around 60 per cent of the country’s insulin supply. Speaking to BW Businessworld in an exclusive interaction, John C Dawber, CVP and MD, Global Business Services talks about the company’s GLP1 growth story, the market of obesity drugs and their safety profile and building capacities and partnerships
Read More
An insight into Jaipur Rugs' commitment to artisan empowerment, innovation, and sustainable practices in the rug industry
Read More
This impressive figure stands in stark contrast to the industry's average CAGR of 15-20 per cent, says NTT’s Shekhar Sharma
Read More
Currently, around 40 per cent of Arrcus' workforce is based in Bengaluru
Read More
In an exclusive interview with BW Businessworld, Mahesh Anand, President of Nippon Paint India's Decorative Division, talks about the company’s commitment to sustainability and empowering painters
Read More
In an interview, Pratima Harite, Head of AP CSR and Philanthropy at Lenovo, talks about empowering youth for a tech-driven future
Read More
In an exclusive interview with Bikram Singh Bedi, Managing Director at Google Cloud, India region, BW Businessworld delves into the immense opportunities India presents for Google Cloud amidst its ongoing digital transformation
Read More
In an interview with BW Businessworld, Chintan Ghelani, Associate Partner, Direct Taxation, N.A. Shah Associates provides important insights for both first-time taxpayers and regular taxpayers
Read More
Sanket Atal, Managing Director, Operations & Site Lead-Technology, Salesforce, shares Insights on the importance of aligning the workforce with the changing demands of the job market and the company's youth skill development initiatives
Read More
Startups and tech companies across industries are being valued today at mountain-high valuations, with investors sprinkling the dry powder and founders aiming for volumes, scale and consolidation and not minding the losses. But the industry today is also not new to certain post-listing debacles of tech companies and a recent valuation turnaround of a health-tech company PharmEasy lowering its valuations by 90 per cent to fund its debt
Read More
